Evidence map›Paper›PMID 36223679›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2022

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

Vincenzo Di Noia, Fulvia Pimpinelli, Davide Renna, Flaminia Campo, Antonella Cosimati, Andrea Torchia, Benedetta Marcozzi, Alice Massacci, Matteo Pallocca, Raul Pellini and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Vincenzo Di NoiaMedical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: vincenzo.dinoia@ifo.it.
Fulvia PimpinelliMicrobiology and Virology Unit, Dermatological Clinical Department, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Davide RennaMedical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Flaminia CampoOtolaryngology Head and Neck Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Antonella CosimatiDepartment of Clinical and Molecular Medicine, Università La Sapienza di Roma, Italy.
Andrea TorchiaDepartment of Clinical and Molecular Medicine, Università La Sapienza di Roma, Italy.
Benedetta MarcozziBiostatistic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Alice MassacciBiostatistic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Matteo PalloccaBiostatistic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Raul PelliniOtolaryngology Head and Neck Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Aldo MorroneScientific Direction, Dermatological Clinical Department, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Francesco CognettiPresident of FOCE, ConFederazione Oncologi-Cardiologi-Ematologi, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Complementary TherapiesNeoplasmsVaccinesBNT162 VaccineHumansImmunity, HumoralBNT162 VaccineVaccines

Identifiers

PMID36223679
PMCPMC9548024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.